This study compared HbA1c control, treatment patterns, and costs in adults with T2DM initiated on CANA or a GLP-1 based on administrative claims data from the HealthCore Integrated Research Database (4/2013-02/2016) augmented with laboratory data. The analysis included adult patients with ≥1 HbA1c result at baseline (BL) and in the 12-month follow-up period; statistical analysis was performed at 3-month intervals. Inverse probability of treatment weighting (IPTW) accounted for differences in BL characteristics. From 12 months pre- to 12 months post-index (Figure), there were no significant differences in HbA1c at each 3-month interval in patients initiated on CANA (n = 750) or GLP-1 (n = 2417); results were consistent regardless of BL HbA1c (≥7%, ≥8%, or ≥9%) (data not shown). A greater proportion of patients were adherent to index medication (proportion of days covered ≥80%) over 12 months with CANA vs. GLP-1 (47.5% vs. 37.5%; P <0.001). The likelihood of discontinuation from index medication was lower with CANA than GLP-1 (49.6% vs. 57.4%; HR [95% CI]: 0.78 [0.70, 0.88]). Continuous 12-month pharmacy costs were $1,421 lower with CANA vs. GLP-1.

In summary, CANA initiation resulted in similar HbA1c values, greater adherence, less discontinuation, and lower treatment cost compared to GLP-1 in T2DM patients.

graphic
View largeDownload slide
Disclosure

M. Singhal: Other Relationship; Self; Janssen Scientific Affairs, LLC. H. Tan: Other Relationship; Self; Janssen Scientific Affairs, LLC. C.I. Coleman: Research Support; Self; Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc. W.H. Herman: Other Relationship; Self; Merck Sharp & Dohme Corp., Lexicon Pharmaceuticals, Inc.. Consultant; Self; Janssen Scientific Affairs, LLC.. Research Support; Spouse/Partner; Nestlé. Other Relationship; Self; American Diabetes Association. Advisory Panel; Self; National Committee for Quality Assurance (NCQA). J. Cai: Employee; Self; Janssen Scientific Affairs, LLC. M. Han: Employee; Self; Janssen Scientific Affairs, LLC. M. Ingham: Employee; Self; Janssen Scientific Affairs, LLC..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.